Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
What Is Semax? Benefits, Research & Safety
A synthetic peptide based on ACTH, developed in Russia as a nootropic and neuroprotectant, approved there for cognitive disorders and stroke.
Also known as:
MEHFPGP
Semax Acetate
UK summary: Not a licensed UK medicine. Russian-developed nootropic peptide derived from ACTH; used in Russia for some neurological indications. Most published evidence is from Russian groups with limited independent replication.
Quick Facts
Category
Cognitive & Neurological
Half-Life
Short plasma half-life; CNS effects persist longer
UK Status
Not licensed. Research compound only.
EU Status
Not approved by EMA. Not available as a pharmaceutical.
Overview
Semax is a synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-7) with an added Pro-Gly-Pro sequence that enhances stability. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Semax is approved in Russia and several other countries for the treatment of cognitive disorders, stroke, and attention deficit.
Unlike the parent ACTH molecule, Semax does not have hormonal (corticotropic) effects. Instead, it demonstrates primarily nootropic (cognition-enhancing) and neuroprotective properties. Research suggests it can enhance memory, learning, attention, and provide protection against various forms of neural damage.
Semax is typically administered intranasally and has been used in Russia for over 25 years. It is prescribed for a range of conditions including cognitive impairment after stroke, attention deficit disorders, and as an adjunct in optic nerve diseases.
The peptide is also reported to have immunomodulatory properties and has been studied for effects on gene expression related to neurotrophic factors and immune function.
Semax is not approved for use in the UK, EU, or USA, where it remains a research compound.
Evidence standards summary
Semax — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
CLimited human evidenceOverall grade against our evidence grading methodology.
Not a licensed UK medicine. Russian-developed nootropic peptide derived from ACTH; used in Russia for some neurological indications. Most published evidence is from Russian groups with limited independent replication.
02Human evidence grade
DAnimal/cell evidence onlyStrength of evidence from published human trials.
03Preclinical evidence grade
CLimited human evidenceAnimal-model and in-vitro evidence quality.
04Regulatory status
- UK: Not licensed. Research compound only.
- EU: Not approved by EMA. Not available as a pharmaceutical.
- Notes: Semax is approved in Russia and several other countries. It is not approved in Western countries. Products from non-pharmaceutical sources may have quality and authenticity concerns.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Reverses cognitive decline in healthy adults.
- Equivalent to modafinil with no side effects.
- Speeds stroke recovery on par with NHS neurorehabilitation.
- Safe for daily long-term cognitive enhancement.
07Common internet claims
- Marketed as an ACTH-derived smart drug for exam prep and high-stakes work.
- Sold as a stroke-recovery nootropic by grey-market nasal-spray retailers.
- Recommended in biohacker stacks alongside Selank, methylene blue, and racetams.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Improves cognitive function in healthy adults” | C | Limited | Moderate | Russian-language studies report cognitive effects in clinical populations; healthy-adult cognitive-enhancement claims are not well established. |
| “Neuroprotective after stroke” | C | Yes | Moderate | Approved for stroke recovery in Russia; not UK-licensed for this indication and not on NHS pathways. |
| “Safer than prescription nootropics” | E | No | High | Comparative safety claims need comparative trials. |
09Safety uncertainty score
High
Limited human safety data; meaningful uncertainty about rare or long-term effects.
10Known adverse signals
- Nasal irritation and sneezing.
- Headache, fatigue, and altered mood reported anecdotally.
- Unknown effects of chronic BDNF/melanocortin pathway activation.
- Drug-drug interactions with antidepressants, stimulants, and steroids not characterised.
11Drug-interaction uncertainty
High
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
WADA: Sport status unclearWADA strict-liability framing applies.
13UK legal position
UK: Unlicensed (UK)
Not licensed. Research compound only.
14EU legal position
Not approved by EMA. Not available as a pharmaceutical.
15What this page cannot tell you
- Whether a UK-purchased nasal spray contains Semax at the labelled concentration.
- How it interacts with SSRIs, methylphenidate, or atomoxetine in adult ADHD patients.
- Whether long-term use changes endogenous melanocortin or BDNF tone.
- What the WADA in-competition status is for athletes.
16Last reviewed
17Citation quality score
DAnimal/cell evidence onlyQuality of the sources we cite, graded against the evidence grading methodology.
18Research gaps
- Most positive human evidence comes from Russian-language journals without independent replication.
- No Western Phase 3 cognitive-outcome trials.
- Long-term safety unstudied in non-Russian populations.
- Mechanism of nootropic action incompletely characterised.
19Safer alternatives / established care pathways
- NHS post-stroke rehabilitation pathway (occupational therapy, neuro-physio, speech and language therapy).
- GP review for adult ADHD assessment if attention is the underlying concern.
- Structured sleep, exercise, and caffeine review before adding a compound.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Semax a licensed UK medicine?
- If I'm researching neurological recovery, what UK-licensed pathways exist?
- What is the quality of the Russian evidence base?
Discovery & History
Semax was developed in the 1980s and 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences. The development was led by Professor Nikolay Myasoedov, who also developed Selank.
The peptide was designed based on ACTH 4-7, a fragment of adrenocorticotropic hormone that had been found to have cognitive effects independent of the hormone's primary function of stimulating cortisol release. Researchers added a stabilising Pro-Gly-Pro sequence to create a more metabolically stable compound.
Preclinical research demonstrated nootropic effects, including enhanced learning and memory in various animal models. Studies also revealed neuroprotective properties, with Semax protecting neurons against various forms of damage.
Semax received regulatory approval in Russia in the 1990s and has been used clinically there for conditions including stroke rehabilitation, cognitive impairment, and attention disorders. It has been included in Russian treatment guidelines for stroke and optic nerve diseases.
Extensive research has been conducted in Russia, though Western peer-reviewed literature remains more limited. The peptide continues to be studied for mechanisms and potential applications.
Mechanism of Action
Semax exerts its effects through multiple mechanisms:
**BDNF Upregulation**
One of the most significant effects of Semax is increased expression of brain-derived neurotrophic factor (BDNF) and its receptor TrkB. BDNF is crucial for neuroplasticity, neuronal survival, and cognitive function.
**NGF and Other Neurotrophins**
Semax also increases expression of nerve growth factor (NGF) and other neurotrophic factors, supporting neuronal health and plasticity.
**Melanocortin Receptor Effects**
While lacking ACTH's hormonal activity, Semax may interact with melanocortin receptors in the brain, which are involved in cognition, motivation, and neuroprotection.
**Dopaminergic and Serotonergic Modulation**
Research indicates effects on dopamine and serotonin systems, which may contribute to cognitive and mood effects.
**Gene Expression Modulation**
Semax affects the expression of numerous genes, including those involved in neurotransmitter function, oxidative stress responses, and immune regulation.
**Anti-Inflammatory Effects**
The peptide has demonstrated anti-inflammatory properties in the brain, potentially contributing to neuroprotection.
**Immunomodulation**
Semax possesses immunomodulatory effects, influencing cytokine production and immune cell function.
Researched Benefits
Based on preclinical and clinical research findings:
- 1Enhanced memory and learning in animal and human studies
- 2Neuroprotective effects in stroke and brain injury models
- 3Increased BDNF and neurotrophic factor expression
- 4Improved attention and focus
- 5Potential benefits in optic nerve diseases
- 6Anti-inflammatory effects in the CNS
- 7Possible mood-stabilising effects
Claim vs Evidence
How popular claims about Semax stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Improves cognitive function in healthy adults” | C | Limited | Moderate | Russian-language studies report cognitive effects in clinical populations; healthy-adult cognitive-enhancement claims are not well established. |
| “Neuroprotective after stroke” | C | Yes | Moderate | Approved for stroke recovery in Russia; not UK-licensed for this indication and not on NHS pathways. |
| “Safer than prescription nootropics” | E | No | High | Comparative safety claims need comparative trials. |
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | 200-600 mcg intranasally per dose (Russian clinical standard) |
| Frequency | 2-3 times daily |
| Duration | 10-14 days typically, can be extended for certain conditions |
| Notes | These protocols reflect Russian pharmaceutical use. Semax is not approved in the UK/EU. Intranasal administration is standard. Higher doses (1% solution) may be used for certain conditions in Russia. |
Administration Routes
Routes studied in research settings (educational only):
- Intranasal (nasal drops or spray - most common)
- Subcutaneous injection (less common)
| Half-Life | Stability |
|---|---|
| Short plasma half-life; CNS effects persist longer | Nasal formulations stable under appropriate storage conditions |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Generally well-tolerated in Russian clinical use
- Mild nasal irritation
- Headache (rare)
- Transient blood pressure changes (rare)
Rare Risks & Concerns
- Limited long-term safety data from Western studies
- Effects on hormonal systems with chronic use unknown
- Potential for drug interactions not fully characterised
Contraindications
- Pregnancy and breastfeeding
- Active seizure disorders (precautionary)
- Known allergy to peptide components
- Acute psychosis (precautionary)
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed. Research compound only.
🇪🇺 European Union
Not approved by EMA. Not available as a pharmaceutical.
Semax is approved in Russia and several other countries. It is not approved in Western countries. Products from non-pharmaceutical sources may have quality and authenticity concerns.
Clinical Studies Summary
Semax in the Treatment of Acute Ischemic Stroke
Russian clinical studies demonstrating neuroprotective effects and improved outcomes in stroke patients.
Zh Nevrol Psikhiatr Im S S Korsakova (Russian)View on PubMed
Effects of Semax on Gene Expression in the Brain
Research demonstrating Semax's effects on BDNF, NGF, and other neurotrophic factor expression.
Various publicationsView on PubMed
Looking for Semax?
Source research-grade Semax from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Semax
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Semax a licensed UK medicine?
- If I'm researching neurological recovery, what UK-licensed pathways exist?
- What is the quality of the Russian evidence base?
UK regulatory & safety context
Related Research Guides
Peptide Comparisons
Combination Protocols
Related Peptides
Selank
A synthetic peptide based on tuftsin, developed in Russia for anxiolytic and nootropic properties, approved there for anxiety and neurasthenia.
Learn moreDSIP
A neuropeptide originally isolated for its sleep-inducing properties, now researched for stress protection, pain modulation, and metabolic effects.
Learn moreBDNF
A critical growth factor for brain health, neuroplasticity, and neuronal survival, with implications for depression, memory, and neurodegenerative diseases.
Learn more